Five Year Summary
2014
2015
2016
2017
2018
Dose sales (units)
8,561
10,252
11,931
12,578
11,861
Sales revenue ($'000)
129,363
176,088
232,492
234,282
218,735
Profit / (loss) before income tax ($'000)
31,110
52,768
69,998
(40,954)
59,271
Net profit / (loss) ($'000)
23,868
40,345
53,582
(26,257)
41,469
R&D investment ($'000)
7,981
8,641
10,835
11,865
2,228
Clinical investment ($'000) *
22,168
20,724
20,631
24,852
7,991
Capital investment ($'000)
6,187
1,692
1,718
1,239
673
Total assets at 30 June ($'000)
148,710
201,476
261,717
194,122
221,009
Total equity at 30 June ($'000)
107,583
144,636
193,504
149,467
159,177
Net tangible assets at 30 June ($'000)
60,219
76,609
110,683
140,941
150,919
Earnings (loss) per share (cents)
42.5
71.4
93.7
(45.5)
73.9
Dividends per share (cents)
14
20
30
30
0

* Excludes SIRFLOX amortisation expense

 



Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×